Retinal Diseases Clinical Trial
Official title:
Effect of Levodopa on Human Multifocal Electroretinogram
It is known that dopamine is a functional neuromodulator at several levels of the visual system. Dopamine seems to be involved in the organization of the ganglion cell and the bipolar cell receptive fields and modulation of physiological activity of photoreceptors. There is evidence for the functional significance of dopaminergic modulation of visual sensitivity in humans which confirms the hypothesis that dopamine plays an important role in retinal light adaptation as well as in motion and contrast sensitivity function. The electrophysiological effects of dopamine, various dopamine antagonist and levodopa in animals and humans have been investigated by means of visual evoked potentials and electroretinograms. The multifocal ERG technique, developed by Sutter et al. allows a rapid, simultaneous recording of focal ERGs from multiple retinal locations. Although this technique is relatively new, it has already provided insights into the mechanisms of retinal diseases (e.g. involvement of visual system in Parkinson disease), but until now there is no data on influence of dopaminergic substances on mERG.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04968756 -
Evaluating the Safety of the SPECTRALIS CENTAURUS Device
|
N/A | |
| Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT00437593 -
UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue
|
N/A | |
| Completed |
NCT04919473 -
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
| Completed |
NCT01205035 -
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
|
Phase 2 | |
| Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
| Active, not recruiting |
NCT06071546 -
Clinical Investigation of a New Version of MAIA Microperimeter on Healthy Subjects and Patients With Retinal Pathology
|
N/A | |
| Completed |
NCT02946879 -
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
|
||
| Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
| Recruiting |
NCT04592068 -
AI Classifies Multi-Retinal Diseases
|
||
| Completed |
NCT01746563 -
Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy
|
Phase 1/Phase 2 | |
| Completed |
NCT01399515 -
Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
|
Phase 2 | |
| Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT03954626 -
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
|
Phase 3 | |
| Completed |
NCT02582164 -
Long-Working Distance OCT for Children
|
N/A | |
| Completed |
NCT01790958 -
Microcurrent Stimulation to Treat Macular Degeneration
|
N/A | |
| Recruiting |
NCT05283941 -
Pistachios and Neural Macular Pigment
|
N/A | |
| Completed |
NCT04678375 -
Artificial Intelligence for Detecting Retinal Diseases
|
||
| Completed |
NCT04902170 -
Long-shaft Vitrectomy Probe in Highly Myopic Eyes
|
N/A | |
| Completed |
NCT02543229 -
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
|
Phase 1 |